Navigation Links
Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
Date:8/11/2008

- Conference Call Today at 4:30 p.m. Eastern Time -

SAN FRANCISCO, Aug. 11 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today reported on its corporate progress and financial results for the quarter ended June 30, 2008.

"Based on the significant findings of the Dimebon 12-month pivotal trial in Alzheimer's disease recently published in The Lancet, as well as the promising results from our Phase 2 study in Huntington's disease announced last month, we believe Dimebon is among the most promising drug candidates being investigated today to treat patients with debilitating, and ultimately fatal, neurodegenerative diseases," said David Hung, M.D., president and chief executive officer of Medivation. "We are making excellent progress opening U.S. sites and enrolling patients in our confirmatory Phase 3 trial of Dimebon in Alzheimer's disease, and remain on target to complete the study in time to file for U.S. marketing approval for Alzheimer's disease in 2010. In addition, we continue to increase the dose and enroll patients in our ongoing Phase 1-2 study of MDV3100 for castration-resistant prostate cancer. We remain on track for completing that study later this year, after which we intend to seek FDA approval to enter Phase 3 in 2009."

Second Quarter Highlights and Recent Accomplishments

Alzheimer's Disease

-- Initiated dosing of patients in a second pivotal Phase 3 trial of the

investigational drug Dimebon in patients with mild-to-moderate

Alzheimer's disease. This international, double-blind,

placebo-controlled safety and efficacy study of oral Dimebon, known as

the CONNECTION study, will enroll approximately 525 patients at 60 to

80 cl
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
2. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
3. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
4. Medivation Announces Senior Management Promotions
5. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
6. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
7. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... (PRWEB) August 21, 2014 His Majesty ... Opening , The Court of His Majesty Willem-Alexander, King ... attend the Grand Opening of POET-DSM Advanced Biofuels’ Project ... Sept. 3. , The King will take part in ... activity, scheduled for 11 a.m.-12:20 p.m. and tour the ...
(Date:8/21/2014)... , Aug. 21, 2014  Decision Resources Group ... Brazil and Mexico ... of several newly approved agents, the anticipated label ... and the launch of emerging biologics will substantially ... particular, the emerging IL-5 inhibitors will introduce a ...
(Date:8/21/2014)... , Aug. 21, 2014  China Cord Blood Corporation ... its plan to release financial results for the first ... 2014, after market close in the US.  ... 8:00 a.m. ET on Friday, August 29, 2014 to ... of the Company,s recent developments, followed by a question ...
(Date:8/21/2014)... August 21, 2014 Ontotext S4 ... by Ontotext . Now the same enterprise ... of structured and unstructured data is available to start-ups ... of enterprise technology. Organizations that do not have resources ... management can use S4 since there is no need ...
Breaking Biology Technology:His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4
... NEW YORK , May 28 ... an international biopharmaceutical company,with operations in the U.S. and China , ... , BSN, RN, HP (ASCP), has been,selected to present at the American ... . , , , ...
... A research ... gene transfer from host to parasite plant species. The discovery, reported in Science this week, ... ... A research team at RIKEN, Japan’s flagship research organization, has uncovered the first ever evidence ...
... May 27 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE,Amex: ... operations in the U.S. and China , announced that ... technologies at the Stem Cell,Investor & Executive Networking Conference Event ... 2010 . SCIENCE is designed to bring together investors with ...
Cached Biology Technology:NeoStem Selected to Present at American Society for Apheresis 2NeoStem Selected to Present at American Society for Apheresis 3NeoStem Selected to Present at American Society for Apheresis 4Parasite plants rob genes from their hosts 2NeoStem's Advanced Adult Stem Cell Technology to be Featured at Upcoming Conference 2NeoStem's Advanced Adult Stem Cell Technology to be Featured at Upcoming Conference 3NeoStem's Advanced Adult Stem Cell Technology to be Featured at Upcoming Conference 4NeoStem's Advanced Adult Stem Cell Technology to be Featured at Upcoming Conference 5
(Date:8/21/2014)... Nine researchers from Beth Israel Deaconess Medical Center ... "The World,s Most Influential Scientific Minds 2014," a ... ScienceWatch, a web resource for science metrics and research ... among the most influential "are performing and publishing work ... of their science," according to a Thomson Reuters statement. ...
(Date:8/21/2014)... in the journal Carcinogenesis by researchers at ... the protein adenomatous polyposis coli (APC) in suppressing colorectal ... the U.S. , Lead author Kristi Neufeld, associate professor ... the Cancer Biology program at the KU Cancer Center, ... to understand the various activities of APC, a protein ...
(Date:8/21/2014)... Acute pancreatitis involves the pancreas digesting itself resulting in ... in the UK around 20,000 patients are diagnosed with ... immediate cure and treatment is restricted to intravenous fluid ... the Faculty of Life Sciences, who led the research, ... reflux from gall stones and excessive alcohol intake combined ...
Breaking Biology News(10 mins):BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3Research offers insight into cellular biology of colorectal cancer 2Research offers insight into cellular biology of colorectal cancer 3Insulin offers new hope for the treatment of acute pancreatitis 2
... Scientists at The University of Nottingham and the Wellcome Trust ... that control the three key stages in the life cycle ... third of these switches can be disrupted in some way. ... and the Medical Research Council (MRC) is a significant breakthrough ...
... journal, Science Translational Medicine , examines the structures ... commentary has been written by researchers from the National ... (BRC) at Guy,s and St Thomas, and King,s College ... Government and charitable investment in translational research taking place ...
... Health Sciences Center New Orleans has been awarded $12 ... Health to conduct research on diseases like prostate and ... herpes infections, as well as to support the development ... round of funding for a $10.6 million Center of ...
Cached Biology News:Malaria research begins to bite 2Malaria research begins to bite 3Strategies for translational research in the UK 2LSUHSC awarded $12 million for cancer, infectious diseases research & research pipeline 2LSUHSC awarded $12 million for cancer, infectious diseases research & research pipeline 3
GOAT ANTI HUMAN FACTOR 8RELATED ANTIGEN...
2,4,6-Trinitrophenyl hapten is conjugated to Bovine Serum Albumin protein through lysine by amide bonds....
EoProbe Eosinophil Staining Kit, 1 Kit...
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
Biology Products: